Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares, rose in value on Thursday, March 06, with the stock price up by 1.84% to the previous day’s close as strong demand from buyers drove the stock to $17.67.
Actively observing the price movement in the last trading, the stock closed the session at $17.35. Referring to stock’s 52-week performance, its high was $35.80, and the low was $16.57. On the whole, ARWR has fluctuated by -10.21% over the past month.
With the market capitalization of Arrowhead Pharmaceuticals Inc currently standing at about $2.23 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 118.54M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ARWR’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ARWR currently trading nearly -8.17% and -9.08% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.47, while the 7-day volatility ratio is showing 5.35% which for the 30-day chart, stands at 5.61%. Furthermore, Arrowhead Pharmaceuticals Inc (ARWR)’s beta value is 0.87, and its average true range (ATR) is 1.07.
A comparison of Arrowhead Pharmaceuticals Inc (ARWR) with its peers suggests the former has fared considerably weaker in the market. ARWR showed an intraday change of 1.84% in last session, and over the past year, it shrunk by -49.67%%.
Data on historical trading for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) indicates that the trading volumes over the past 3 months, they’ve averaged 1.84 million. According to company’s latest data on outstanding shares, there are 125.57 million shares outstanding.
Nearly 16.77% of Arrowhead Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 77.04% of the company’s shares. The stock has fallen by -6.01% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ARWR stock heading into the next quarter.
